FDA Expands Guselkumab Label in PsA - Top-Institutions - MDSpire

FDA Expands Guselkumab Label in PsA

  • By

  • Kathryn Wighton

  • May 29, 2026

Share

Top Institutions in Rheumatology

Brief introduction explaining scope and methodology.

  • #1

    Swedish Medical Center
    Swedish Medical Center

    Seattle, WA

    Key Differentiators

    • Rheumatology

  • #2

    Providence St. Joseph Health
    Providence St. Joseph Health

    Renton, WA

    Key Differentiators

    • Rheumatology

  • #3

    University of Washington School of Medicine
    University of Washington School of Medicine

    Seattle, WA

    Key Differentiators

    • Rheumatology

  • #4

    Weill Cornell Medicine
    Weill Cornell Medicine

    New York, NY

    Key Differentiators

    • Rheumatology

Original Source(s)

FDA Expands Guselkumab Label in PsA

  • by Kathryn Wighton

  • May 29, 2026

Related Content

RA Outcomes Improved in KURAMA Cohort

Ten-year observational data showed lower disease activity and functional disability coinciding with broader use of biologic and targeted synthetic therapies.

JAK Monotherapy Shows Efficacy in RA Review

A systematic review found Janus kinase inhibitor monotherapy improved outcomes vs methotrexate or placebo, but direct comparisons with combination therapy were limited.

FDA Clears Golimumab Biosimilars

New biosimilars enter the market with pharmacy-level substitution eligibility for rheumatology and gastroenterology indications.